ALSO READGlenmark Pharma gets USFDA nod for generic skin ointment Glenmark Pharma's generic anti-inflammatory drug gets USFDA nod USFDA issues warning letter to Telangana unit of Vista Pharmaceuticals Glenmark gets USFDA's approval to sell generic blood pressure medicine Risk-reward favourable for Glenmark
Glenmark Pharmaceuticals on Monday said its US-based arm has received final approval from the United States Food & Drug Administration (USFDA) for Aprepitant capsules, used for preventing nausea caused by cancer chemotherapy.
The tablets are generic versions of Merck Sharp & Dohme Corporation's Emend capsules, it added.
According to IMS health sales data for the 12 months ended August, Emend Capsules, 40 mg, 80 mg, and 125 mg achieved annual sales of around $64.9 million, Glenmark said.
The company's current portfolio consists of 127 products authorised for distribution in the US marketplace and 60 abbreviated new drug applications (ANDAs) which are pending approval with the USFDA, it added.
Shares of Glenmark Pharmaceuticals rose by 0.63 per cent to Rs 607 in morning trade on BSE.